Cullinan Therapeutics (CGEM) Other financing activities (2021 - 2022)

Cullinan Therapeutics' Other financing activities history runs 3 years deep, the most recent figure standing at $1.2 million for Q1 2022.

• In Q1 2022, Other financing activities fell 99.57% year-over-year to $1.2 million; the TTM figure through Dec 2022 stood at $1.2 million (up 24.92% YoY), while the FY2022 annual figure was $1.2 million, up 24.92% from the prior year.
• Other financing activities for Q1 2022 stood at $1.2 million, up from -$266.3 million in the prior quarter.
• The five-year high for Other financing activities was $267.3 million in Q1 2021, with the low at -$266.3 million in Q2 2021.
• The 3-year median for Other financing activities is $1500.0 (2020), against an average of $231500.0.
• Peak annual rise in Other financing activities reached 99.57% in 2022, while the deepest fall reached 99.57% in 2022.
• Cullinan Therapeutics' Other financing activities stood at -$1.2 million in 2020, then tumbled by 23060.43% to -$266.3 million in 2021, then jumped by 100.43% to $1.2 million in 2022.
• Business Quant data shows CGEM's Other financing activities at $1.2 million in Q1 2022, -$266.3 million in Q2 2021, and $267.3 million in Q1 2021.